Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
The remarkable progress in engineering and clinical development of therapeutic antibodies in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by the United States Food and Drug Administration (FDA) of 21 antibodies for cancer immunotherapy. We review here the...
Main Authors: | Juan C. Almagro, Tracy R. Daniels-Wells, Sonia Mayra Perez-Tapia, Manuel L. Penichet |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01751/full |
Similar Items
-
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
by: Pierre V. Candelaria, et al.
Published: (2021-03-01) -
Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells
by: Jesse D. Plotkin, et al.
Published: (2019-02-01) -
Next-Generation Sequencing of Antibody Display Repertoires
by: Romain Rouet, et al.
Published: (2018-02-01) -
Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates
by: Andrew E Nixon, et al.
Published: (2015-04-01) -
An efficient strategy for cell-based antibody library selection using an integrated vector system
by: Yoon Hyerim, et al.
Published: (2012-09-01)